Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed

Executive Summary

Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.

You may also be interested in...



Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did

Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.

Deal Watch: Oncology A Recurring Theme In Recent Spate Of Transactions

TetraLogic uses cash from its recent IPO to bring form to its oncology pipeline via the acquisition of Shape Pharmaceuticals. Also, GlaxoSmithKline becomes the latest big pharma to partner with MD Anderson Cancer Center’s Moon Shots program and Mersana will collaborate with Takeda on antibody-drug conjugates for cancer.

Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback

GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it put more pressure on the company to deliver on its respiratory launches.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel